ArticleThe British journal of ophthalmology2007
Expression of vascular endothelial growth factor and its receptors in rosacea.
Article in The British journal of ophthalmology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 98 citations in OpenAlex.
- Article
- Increased Expression of Angiopoietin 2 and Tie2 in Rosacea.Dermatopathology (Basel, Switzerland) · 2025Article
- The role of skin barrier and immune abnormalities in the pathogenesis of Rosacea.Clinical and experimental medicine · 2025Review
- Targeting Vascular and Inflammatory Crosstalk: Cannabigerol as a Dual-Pathway Modulator in Rosacea.International journal of molecular sciences · 2025Article
- Social Isolation During COVID-19 Pandemic: Challenges of a Rhinophyma Patient Reluctant to Seek Treatment.Cureus · 2025Article
- Research progress in the role of ultraviolet in the pathogenesis of rosacea.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2025Review
- Signaling pathways and targeted therapy for rosacea.Frontiers in immunology · 2024Review
- Exploring the Pathogenesis and Mechanism-Targeted Treatments of Rosacea: Previous Understanding and Updates.Biomedicines · 2023Review
- Increased Risk of Glaucoma in Patients with Rosacea: A Nationwide Population-Based Cohort Study.Journal of clinical medicine · 2023Article
- Association between the Treatment of Rosacea and Eradication ofAdvanced biomedical research · 2023Article
- Rosacea, microbiome and probiotics: the gut-skin axis.Frontiers in microbiology · 2023Review
- Article
- Inhibition of Hippo Signaling Improves Skin Lesions in a Rosacea-Like Mouse Model.International journal of molecular sciences · 2021Article
- Cutaneous and ocular rosacea: Common and specific physiopathogenic mechanisms and study models.Molecular vision · 2021Review
- mTORC1-Mediated Angiogenesis is Required for the Development of Rosacea.Frontiers in cell and developmental biology · 2021Article
- The Pathogenic Role of Demodex Mites in Rosacea: A Potential Therapeutic Target Already in Erythematotelangiectatic Rosacea?Dermatology and therapy · 2020Review
- Vascular endothelial growth factor signaling requires glycine to promote angiogenesis.Scientific reports · 2017Article
- Roles of Erythroid Differentiation Regulator 1 (Erdr1) on Inflammatory Skin Diseases.International journal of molecular sciences · 2016Review
- Topical Ivermectin 10 mg/g and Oral Doxycycline 40 mg Modified-Release: Current Evidence on the Complementary Use of Anti-Inflammatory Rosacea Treatments.Advances in therapy · 2016Review
- Molecular and Morphological Characterization of Inflammatory Infiltrate in Rosacea Reveals Activation of Th1/Th17 Pathways.The Journal of investigative dermatology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
backgroundRosacea is a common chronic disease of unclear pathogenesis, characterised by inflammation and vascular abnormalities of the facial skin and ocular surface. Recognising that vascular endothelial growth factor (VEGF) is vasoactive and has inflammatory activities, the expression of this molecule and its receptors, VEGF-R1 and VEGF-R2, in rosacea was investigated.
methodsFormalin-fixed, paraffin wax-embedded sections of skin obtained from 20 patients with rosacea were immunostained to detect expression of VEGF, VEGF-R1 and VEGF-R2, using an indirect methodology incorporating antigen retrieval. Adjacent sections were stained with haematoxylin and eosin.
resultsBiopsy specimens were characterised by perivascular and perifollicular lymphohistiocytic infiltration and dilated vascular channels. In addition to keratinocyte and epithelial staining, which was also noted in normal skin, vascular endothelium frequently stained positive for VEGF-R1 (14/20, 70%) and VEGF-R2 (20/20, 100%), but infrequently for VEGF (2/20, 10%). In most specimens, infiltrating leucocytes, including lymphocytes, macrophages and plasma cells, expressed VEGF (17/20, 85%), VEGF-R1 (20/20, 100%) and VEGF-R2 (20/20, 100%).
conclusionExpression of VEGF receptors, both by vascular endothelium and infiltrating mononuclear cells, is observed in rosacea. Although not expressed by endothelium, VEGF is present in epidermis and epithelium, and is expressed by infiltrating cells. VEGF receptor-ligand binding may contribute to the vascular changes and cellular infiltration that occurs in rosacea.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.